3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Leukemia, Myeloid, Acute
47
Precursor Cell Lymphoblastic Leukemia-Lymphoma
32
Myelodysplastic Syndromes
27
Multiple Myeloma
20
Recurrence
19
Lymphoma, Non-Hodgkin
15
Lymphoma, B-Cell
14
Lymphoma
14
Leukemia, Lymphocytic, Chronic, B-Cell
13
Ovarian Neoplasms
12
Hematologic Neoplasms
12
Melanoma
11
Pancreatic Neoplasms
10
Myeloproliferative Disorders
10
Burkitt Lymphoma
10
Leukemia
9
Hodgkin Disease
9
Stomach Neoplasms
8
Lymphoma, Large B-Cell, Diffuse
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Leukemia, Biphenotypic, Acute
8
Neoplasms
7
Leukemia, Myelomonocytic, Chronic
7
Colorectal Neoplasms
7
Triple Negative Breast Neoplasms
6
Osteosarcoma
6
Neuroblastoma
6
Neoplasm Metastasis
6
Lymphoma, Mantle-Cell
6
Lymphoma, Follicular
6
Interventions
Cisplatin
6
Platinum
5
Pemetrexed
5
1,2-diaminocyclohexaneplatinum II citrate
5
pembrolizumab
4
atezolizumab
2
Radiotherapy
2
Radiation
2
Nivolumab
2
Ipilimumab
2
Gemcitabine
2
Cyclophosphamide
2
Carboplatin
2
tremelimumab
1
methoxyamine
1
fludarabine
1
decitabine and cedazuridine drug combination
1
cediranib
1
anetumab ravtansine
1
aldesleukin
1
Trioxsalen
1
Tissue Banks
1
Radiotherapy, Intensity-Modulated
1
Proton Therapy
1
Phototherapy
1
Photochemotherapy
1
Pharmacogenomic Testing
1
Pharmaceutical Preparations
1
Interleukin-2
1
Influenza Vaccines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
fludarabine
×
90 days
×
Clear all
NCT07510815
2026-04-06
DUAL-MESO-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled